$ANEB News

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Q2 EPS $(0.05) Beats $(0.13) Estimate

Anebulo Pharmaceuticals Announces Voluntary Delisting From Nasdaq

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Anebulo Pharmaceuticals shares are trading lower after the company announced its intention to voluntarily delist from Nasdaq and deregister with SEC.

Anebulo Pharmaceuticals shares are trading lower after the company announced its intention to voluntarily delist from Nasdaq and deregister with SEC.

Anebulo Pharmaceuticals Voluntarily Delisting Common Shares From Nasdaq, Effective Feb. 27

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

How Do Investors Really Feel About Anebulo Pharmaceuticals Inc?

How Is The Market Feeling About Anebulo Pharmaceuticals Inc?

Anebulo Pharmaceuticals shares are trading lower after the company announced that its Board has decided to commence a cash tender offer as part of its plan to "go private" in lieu of the previously announced reverse stock split.

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

US Stocks Higher; Nasdaq Surges Over 100 Points

Anebulo To Commence $3.50/Shr Cash Tender Offer For Up To 300K Shares As Part Of Plan To Go Private In Lieu Of Reverse Stock Split At Ratio Of Not Less Than 1-For-2,500 And Not Greater Than 1-For-7,500

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Q1 EPS $(0.05) Beats $(0.12) Estimate

We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

AnaptysBio Announces Daniel Faga Anticipated To Be CEO Of Biopharma Co; Upon Deal Close, Royalty Management Company To Manage Royalties Including Jemperli & Imsidolimab; Biopharma Co To Launch With Adequate Capital To Fund Operations For At Least 2 Years